KMT2A and leukemia: Notably, miR-150 has previously been demonstrated to be expressed at lower levels in B-ALL compared to healthy control, including in the poor-outcome subgroup of MLL-rearranged leukemia, and furthermore, miR-150 was found to be downregulated in relapsed B-ALL compared to B-ALL in clinical remission (CR) [65,66,67].